To address the challenges of treating TBI and stroke, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have developed and patented a novel approach combining three
distinct classes of drugs to create a multi-drug combination therapy.
Three
distinct classes of drugs: dopaminergic agonists (such as D - amphetamine), serotonergic agonists (such as LSD), and glutamatergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that closely resemble schizophrenia symptoms in humans.
Not exact matches
«Our computer aided
drug screening process has now identified two new
classes of anti-cancer agents, specifically targeting two
distinct and novel mechanisms underpinning cancer,» said Dr Andrea Brancale from Cardiff University's School
of Pharmacy, who led on the compound's design.